Stockscreener 앱 받기
1.27
0.00%
0.00
전일 마감가:
$1.27
열려 있는:
$1.29
하루 거래량:
107.15K
Relative Volume:
0.23
시가총액:
$37.95M
수익:
-
순이익/손실:
$-64.73M
주가수익비율:
-0.4504
EPS:
-2.82
순현금흐름:
$-53.29M
1주 성능:
+4.10%
1개월 성능:
+0.79%
6개월 성능:
-54.48%
1년 성능:
-93.17%
1일 변동 폭
$1.25
$1.29
1주일 범위
$1.22
$1.29
52주 변동 폭
$0.87
$21.40
An 2 Therapeutics Inc Stock (ANTX) Company Profile
명칭
An 2 Therapeutics Inc
전화
(650) 331-9090
주소
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.27 | 37.95M | 0 | -64.73M | -53.29M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2024-08-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-12 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 개시 | JMP Securities | Mkt Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
모두보기
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December - Defense World
Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO. - Smartkarma
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial - The Manila Times
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - Yahoo Finance
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - TipRanks
Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Denali Therapeutics Announces Topline Results for Regimen G - GlobeNewswire
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - The Manila Times
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Yahoo Finance
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching - Yahoo Finance
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Applied Therapeutics, Inc. - The Malaysian Reserve
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - Business Wire
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Yahoo Finance
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - PR Newswire
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial - GlobeNewswire
Atossa's Endoxifen Shows Dramatic 23.5% Breast Density Reduction in Phase 2 Clinical Trial Results - StockTitan
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - Yahoo Finance
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBC - Marketscreener.com
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator - Business Wire
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - Yahoo Finance
Protara Therapeutics to Present Phase 2 Bladder Cancer Trial Data at Key Oncology Meeting - StockTitan
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment - Weatherford Democrat
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease - Business Wire
Investigational Antiviral Therapy Reduces Long-COVID-Related Fatigue and Sleep Disturbance - Sleep Review
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting - Business Wire
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study - The Manila Times
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 - GlobeNewswire
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times
Grace Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - BioSpace
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):